Abstract:Introduction Recent studies suggested that growth differentiation factor 15 (GDF-15) may indicate heart failure and a constellation of cardiovascular co-morbidities in diabetic patients. Whereas N-terminal prohormone of B-type natriuretic peptide (NT-proBNP) is a cardiac-specific biomarker, GDF-15 is non-tissue-specific and may be a useful marker of global cardiovascular disease (CVD) burden, particularly in diabetes. In this systematic review and meta-analysis, we summarized the effects of elevated GDF-15 on the composite outcome of cardiovascular disease, events, and/or death in diabetic patients. Methods MEDLINE, EMBASE, CINAHL and Cochrane Library were queried for articles published from inception until February 2020. Longitudinal studies that reported data about the relationship between GDF-15 levels and CVD outcomes in diabetic patients were included. Pooled hazard ratios (HRs) for mortality were calculated and presented with 95% confidence intervals (CIs). Prespecified I2 threshold values of 25%, 50%, and 75% were used to indicate low, moderate, and high levels of heterogeneity, respectively. The risk of bias in the included studies was evaluated according to the criteria established by the Cochrane collaboration. Publication bias was assessed using funnel plot analysis. Results Seven studies with a total 15,805 diabetic patients were included (Fig. 1). The median follow-up ranged from 1.5 to 7.9 years. Pooled effect estimate suggested that elevated GDF-15 levels at baseline was associated with an increased risk for composite CVD-related outcome(s) (per standard deviation (SD) increase in log(GDF-15): HR 1.26, 95% CI 1.12-1.42, P = 0.0001, I2 for heterogeneity 85%, n = 15,651 patients) (Fig. 2a). When an unadjusted study was excluded, the pooled effect estimate remained statistically significant, with improvement in heterogeneity (per SD increase in log(GDF-15): HR 1.16, 95% CI 1.11-1.20, P <0.00001; I2 16%, n = 14,732 patients) (Fig. 2b). In four studies that reported an association between GDF-15 and all-cause mortality, the pooled analysis suggested that per SD increase in log(GDF-15) concentration, there was a significant increase in the risk for all-cause death (HR 1.76, 95% CI 1.23-2.53, P = 0.002); however, marked study heterogeneity (I2 92%, P <0.001) was observed (Fig. 2c). The pooled HR for all-cause death and GDF-15 remained significant even after excluding the unadjusted study. Conclusion Findings from this systematic review and meta-analysis suggest that elevated GDF-15 levels are associated with increased risk for incident cardiovascular endpoint(s) including acute cardiovascular events, heart failure and/or all-cause death in diabetic patients.

Significant increase of serum extracellular vesicle-packaged growth differentiation factor 15 in type 2 diabetes mellitus: a cross-sectional study

Diabetes mellitus related biomarker: The predictive role of growth-differentiation factor-15

VEGF Levels in Plasma in Relation to Metabolic Control, Inflammation, and Microvascular Complications in Type-2 Diabetes A Cohort Study

Identification of differentially expressed genes in the endothelial precursor cells of patients with type 2 diabetes mellitus by bioinformatics analysis

Correlations between growth differentiation factor 15 (GDF-15) serum levels and gene polymorphism with type 2 diabetes mellitus

Correlation Between Growth Differentiation Factor-15 and Peripheral Neuropathy in Patients with Type 2 Diabetes Mellitus

Clinical Potential of Extracellular Vesicles in Type 2 Diabetes

Increased concentrations of myeloperoxidase in serum and serum extracellular vesicles are associated with type 2 diabetes mellitus

Integrative biology of extracellular vesicles in diabetes mellitus and diabetic complications

Serum growth differentiation factor 15 is closely associated with metabolic abnormalities in Chinese pregnant women

Role of GDF-15 in diabetic nephropathy: mechanisms, diagnosis, and therapeutic potential

Growth differentiation factor–15 predicts the prognoses of patients with acute coronary syndrome: a meta-analysis

Growth Differentiation Factor 15 As a Composite Diabetic Cardiovascular Disease Indicator Including Heart Failure: A Systematic Review and Meta-Analysis

Associations of GDF-15 and GDF-15/adiponectin Ratio with Odds of Type 2 Diabetes in the Chinese Population

GDF-15 Is Associated with Cancer Incidence in Patients with Type 2 Diabetes

Growth differentiation factor 15 predicts future insulin resistance and impaired glucose control in obese nondiabetic individuals: results from the XENDOS trial

Extracellular vesicles as signaling mediators in type 2 diabetes mellitus

Integrated analyses of growth differentiation factor-15 concentration and cardiometabolic diseases in humans

Association between growth differentiation factor 15 levels and gestational diabetes mellitus: A combined analysis

GDF15 affects venous thrombosis by promoting EndMT through smad2/p-smad2 pathway

Systematic review and bioinformatics analysis of plasma and serum extracellular vesicles proteome in type 2 diabetes